KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.96

Effect of methylcobalamin on capecitabine induced hand-foot syndrome in patients with HER2 negative early breast cancer: multicentre, double blind, randomised, placebo controlled, phase 3 trial.

Yuan Xia, Yingying Zhu, Li Ling, Fei Xu, Yaping Yang, Jinhui Ye, Weige Tan, Zouxiang Chen, Qiang Liu, Wei Wei, Jun Zhang, Ailing Zhang, Lehong Zhang, Erwei Song, Chang Gong

BMJ 390 e084290

PMID40935571
PMCIDPMC12423938
DOI10.1136/bmj-2025-084290
发表日期2025-09-11
入排依据:主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。
已检查 3 张 PubMed Figure,均未识别为 KM 图:Fig 1:CONSORT/入组流程图;Fig 2:森林图/亚组分析图;captionless-figure:AI 判定为 other。
摘要

摘要

OBJECTIVE: To evaluate whether methylcobalamin could effectively and safely prevent hand-foot syndrome in patients with human epidermal growth factor receptor 2 (HER2) negative early breast cancer receiving adjuvant capecitabine treatment. DESIGN: Multicentre, double blind, randomised, placebo controlled, phase 3 trial. SETTING: Seven hospitals in China between January 2022 and February 2024. PARTICIPANTS: Women aged 18-75 years with pathologically confirmed HER2 negative early breast cancer who were scheduled to receive adjuvant capecitabine treatment. INTERVENTIONS: Eligible patients were randomly assigned in a 1:1 ratio to receive methylcobalamin at a dose of 0.5 mg orally, three times daily, or a placebo for a maximum of 24 weeks. MAIN OUTCOME MEASURES: The primary endpoint was the incidence of grade ≥2 hand-foot syndrome occurring for the first time during capecitabine treatment in the intention-to-treat analysis. RESULTS: 234 patients were randomly assigned to receive methylcobalamin (n=117) or placebo (n=117) and were included in the intention-to-treat and safety analysis. Grade ≥2 hand-foot syndrome occurred in 17 (14.5%) of 117 patients in the methylcobalamin group and 34 (29.1%) of 117 patients in the placebo group (risk difference -14.5%, 95% confidence interval -24.9% to -4.1%; one sided P value=0.003). The rate of reduction or discontinuation of capecitabine treatment because of hand-foot syndrome was 7.7% (9 of 117) in the methylcobalamin group and 13.7% (16 of 117) in the placebo group (risk difference -6.0%, 95% confidence interval -13.9% to 1.9%). The two groups showed similar incidence of any other adverse events (88 (75.2%) in the methylcobalamin group and 95 (81.2%) in the placebo group). No methylcobalamin specific adverse events were observed. CONCLUSIONS: Oral methylcobalamin significantly lowered the severity of hand-foot syndrome by reducing the incidence of grade ≥2 symptoms without unexpected safety concerns in women with HER2 negative early breast cancer who were receiving adjuvant capecitabine treatment. The findings support the use of methylcobalamin to prevent capecitabine associated severe hand-foot syndrome in this patient population. TRIAL REGISTRATION: ClinicalTrials.gov NCT05165069.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig 1Fig 1 CONSORT (consolidated standards of reporting trials) diagram of trial
非 KM Figure
Fig 2Fig 2 Subgroup analyses of incidence of grade ≥2 hand-foot syndrome. CI=confidence interval; TNM=tumour node metastasis
非 KM Figure
captionless-figurecaptionless-figure
非 KM Figure